Table 3 Long-term follow-up
Patient no., gender, age (years) | ATO Dosage mg/kg/d | Week 24 | Post-trial long-term follow-up | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
W24 treatment | SLEDAI score | OCS mg/day | W24 SRI-4-R | W24 LLDAS | W52 LLDAS | Severe Flare | At last follow-up | |||||
sustained LLDAS | OCS mg/day | LLDAS duration | Treatment | |||||||||
1. F, 35 | 0.10 | HCQ, THAL, MTX | 8 | 10 | No | No | No | W24, C | No | – | – | – |
2. F, 41 | 0.10 | HCQ | 2 | 2.5 | Yes | Yes | Yes | No | Yes | 0 | 4 y 3 m | HCQ |
3. F, 49 | 0.10 | HCQ | 4 | 7 | Yes | Yes | Yes | No | Yes | 5 | 4 y 2 m | HCQ |
4. M, 37 | 0.10 | HCQ, MTX | 2 | 8 | Yes | No | Yes | No | Yes | 0 | 3 y 5 m | HCQ, MTX |
5. F, 47 | 0.15 | HCQ | 10 | 15 | No | No | Yes | No | Yes | 5 | 4 y | HCQ |
6. F, 30 | 0.15 | HCQ | 6 | 7.5 | No | No | Yes | No | Yes | 7 | 2 y 10 m | HCQ |
7. F, 50 | 0.15 | HCQ | 20 | 2 | No | No | No | W20, R | No | – | – | – |
8. H, 53 | 0.20 | HCQ, MTX | 0 | 5 | Yes | Yes | Yes | No | Yes | 0 | 3 y 6 m | HCQ, MTX |
9. F, 45 | 0.20 | MMF | 4 | 5 | Yes | Yes | No | W100, R | No | – | – | – |
10. F, 23 | 0.20 | HCQ, AZA | 4 | 5 | No | No | No | W80, R/H | No | – | – | – |